About Us
Hunan Xianshi Pharmaceutical Co., Ltd. is located in the Liuyang Economic and Technological Development Zone. Established on May 20, 2021, with a registered capital of RMB 60 million, the company operates a production base spanning 85 mu and is a modern pharmaceutical enterprise integrating the research and development, manufacturing, and sales of both active pharmaceutical ingredients and finished dosage forms.
The company is currently a national high-tech enterprise and a “Specialized, Refined, Distinctive, and Innovative” Little Giant enterprise in Hunan Province. It has established a provincial-level enterprise technology center spanning approximately 5,000 square meters, laying a solid foundation for independent R&D and technological innovation. Its production base comprises multiple manufacturing lines covering APIs, oral solid dosage forms (including tablets, granules, hard capsules, and soft capsules), oral liquid formulations, small‑volume injectables, large‑volume injectables, inhalation preparations, ophthalmic preparations, and Class III medical devices, making it one of the pharmaceutical companies in Hunan with the most comprehensive product‑line portfolio. The company has developed full vertical integration, from in-house API supply to formulation processing, ensuring efficient and synergistic operations across the value chain.
Investment scale
Service-covered terminals
Supply Region
Honorary Patent
Product Center
Formulated product
Raw and auxiliary materials
Appearance:
White crystalline powder
CAS Number:
108-30-5
Appearance:
White to off-white powder
CAS Number:
677007-74-8
Appearance:
White to pale yellow or light brown crystalline powder
CAS Number:
841301-32-4
R&D Center
Xianshi Pharmaceutical R&D Center has established six major R&D platforms, with over 100 R&D personnel and a master's and doctoral degree ratio of over 30%; There are over 90 ongoing research projects covering innovative drugs, high-end generic formulations, and raw materials, covering fields such as antiviral, anti infective, cardiovascular and cerebrovascular, endocrine, oncology, metabolism, and immunology.
MORE +
Raw material development platform
▹ Development and industrialization platform for active pharmaceutical ingredients and excipients. ▹ Focusing on the synthesis of complex compounds, industrial transformation, and green chemistry technology, providing efficient and environmentally friendly raw material solutions.
MORE +
New drug development platform
▹ Core platform for innovative drug design and product development in categories 1 and 2. ▹ Focusing on the discovery of new drug targets, exploring cutting-edge therapies, and promoting breakthroughs in innovative drugs from research and development to clinical practice.
MORE +
Formulation development platform
▹ Development platform for chemical generic drugs and new drug formulations. ▹ Overcome the technical difficulties of high difficulty formulations and develop more patient compliant, safer, and more effective formulation products.
MORE +
Quality Research Platform
▹ Drug quality research and full process quality control support platform. ▹ Collaborate with various process departments to develop new variety analysis methods and establish quality standards, ensuring stable and reliable drug quality throughout the entire process.
MORE +
Clinical Medicine Platform
▹ Professional management platform for drug clinical research. ▹ Responsible for the evaluation, development, and full cycle management of clinical protocols for Class 3 and Class 4 generic drugs and innovative drugs, ensuring compliance and efficiency in clinical research.
MORE +
Project management and registration platform
▹ Integrated platform for full process control and registration application of ongoing projects. ▹ Responsible for project progress and quality supervision, R&D data inspection and declaration material review, ensuring project quality and registration compliance. ▹ Coordinate the writing of project application materials and registration application work, and promote the smooth acquisition of registration approvals for the project.
MORE +
2026/01/09
2025/11/26
Hotline
Address
No. 19, Baizhu Road, Economic and Technological Development Zone, Liuyang City, Changsha, Hunan, China
Copyright © HUNAN XIANSHI PHARMACEUTICAL CO., LTD.
This site supports IPv4 IPv6 .